O2–009 - Re-Challenge Treatment with Platinum-Containing Regimen in Patients with Sensitive Relapsed Small Cell Lung Cancer

Abstract

Among relapsed small cell lung cancer (SCLC) patients, sensitive relapse is relatively chemosensitive and re-challenge with the same regimen as used in the induction chemotherapy has been used historically, however, its efficacy for sensitive relapsed SCLC remains unclear. In our institution, we defined sensitive relapse as treatment-free interval of 90> days, and have tried re-challenge treatment with platinum-containing regimen. Therefore, we retrospectively reviewed SCLC patients who received the first-line chemotherapy (CT) or chemoradiotherapy (CRT) between April 2009 and December 2012. Fifty-four patients received CT or CRT in that period, and sensitive relapse was observed in 16 patients [12 male and 4 female; median age 71 (range 56-83); PS 0/1, 11/5; LD/ED, 6/10]. Median treatment-free interval was 162 days (range 83-238). Three of 16 patients could not receive second line chemotherapy because of rapid progression and poor PS. One had refused all chemotherapies after first progression. Median number of cycles in second line chemotherapy was 4. Four partial responses and 7 stable disease were observed (response rate and disease control rate were 25% and 92%, respectively). Median progression-free survival time was 5.3 months (95% CI, 3.8-6.9 months) and median survival time was 13.4 months (95% CI, 9.4-17.4 months). Toxicities were generally tolerable and manageable. In conclusion, re-challenge treatment with platinum-containing regimen for sensitive relapsed SCLC is worth further evaluation.